ArticlePloS one2026
Mucosal Snare Resection (MSR) in Non-Submucosal Injection Endoscopic Submucosal Excavation (NSI-ESE) for submucosal tumor may not be the preferable choice: A retrospective study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsNon-submucosal injection endoscopic submucosal excavation (NSI-ESE) and mucosal snare resection-assisted endoscopic submucosal excavation (MSR-ESE) are novel techniques for the treatment of gastric submucosal tumors (SMTs). This study aims to evaluate the feasibility, safety, and efficacy differences between these two methods in the management of gastric SMTs.
methodsA retrospective analysis was conducted on 95 eligible patients who underwent endoscopic treatment for gastric SMTs between 01/01/2022 and 31/12/2024, including 41 patients treated with MSR-ESE and 54 with NSI-ESE. Differences in operative time, safety, and cost-effectiveness between the two groups were compared, and multivariate linear regression analysis was performed to investigate the independent impact of the surgical approach on operative time.
resultsThere were no significant differences between the two groups in baseline characteristics, en bloc resection rate, or incidence of adverse events such as intraoperative perforation and delayed bleeding. However, the MSR-ESE group had significantly longer tumor exposure time (6.37 ± 2.98 min vs. 4.61 ± 2.94 min, p = 0.001), tumor excavation time (29.59 ± 9.09 min vs. 24.09 ± 9.87 min, p = 0.007), and total procedure time (35.95 ± 10.23 min vs. 30.63 ± 11.61 min, p = 0.022) compared with the NSI-ESE group. Multivariate regression analysis confirmed that MSR-ESE was an independent factor associated with prolonged tumor exposure time (β = 1.60, p = 0.005) and total procedure time (β = 5.43, p = 0.012). In addition, the surgery-related cost was significantly higher in the MSR-ESE group than in the NSI-ESE group (US$874.94 ± 106.40 vs. US$731.90 ± 108.98, p < 0.038).
conclusionIn the treatment of gastric SMTs, MSR-ESE did not demonstrate any advantages in efficiency or safety compared with NSI-ESE; instead, it resulted in a significantly longer procedure time, more discomfort and increased economic burden. Therefore, the routine use of snare-assisted mucosal resection during ESE is not recommended in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.